HIIT Effects on Cardiometabolic Health

NCT05838950 | Recruiting

• 1 other identifier: 22-010
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The primary aim of this randomized clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group. HIIT-A, HIIT-B, and HIIT-C groups will participate in six sessions of a running based HIIT program over a 2-week training period. Pre-clinical markers of cardiovascular disease, blood lipids and fasting glucose will be measured at the following three time points: baseline, post-intervention, and 2 weeks after the training cessation (i.e., measure for detraining effect). All measurements will be performed three days before the training program and three days after the intervention to avoid the effect of the last training session. Afterwards, the detraining test will be measured 2 weeks post intervention.

Conditions

Obesity; Cardiovascular Diseases; Metabolic Disease; High-intensity Interval Training

Keywords

HIIT; Detraining effects; Cardiometabolic disease; Obesity; Young adults

Outcome Measures

Primary Outcomes (16)

• Height

  Height (cm)

  Baseline

• Weight

  Weight (kg); Change from Baseline weight at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Body mass index

  Body mass index (kg/m2); Change from Baseline BMI at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Percentage body fat

  Percentage body fat (kg); Change from Baseline percentage body fat at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Fat mass

  Fat mass (kg); Change from Baseline fat mass at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Lean mass

  Lean mass (kg); Change from Baseline lean mass at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Systolic blood pressure

  Systolic blood pressure (SBP, mmHg); Change from Baseline SBP at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Diastolic blood pressure

  Diastolic blood pressure (DBP, mmHg); Change from Baseline DBP at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Mean arterial pressure

  Mean blood pressure (MAP, mmHg); Change from Baseline MAP at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Flow-mediated dilation

  Flow-mediated dilation (FMD, mm); Change from Baseline FMD at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Carotid-femoral Pulse Wave Velocity (cPWV)

  cPWV (m/s); Change from Baseline cPWV at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Total cholesterol

  Total cholesterol (mg/dl); Change from Baseline TC at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• LDL-C

  LDL-C (mg/dl); Change from Baseline LDL-C at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• HDL-C

  HDL-C (mg/dl); Change from Baseline HDL-C at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Triglycerides

  Triglycerides (TG, mg/dl); Change from Baseline TG at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

• Glucose

  Glucose (mg/dl); Change from Baseline glucose at 2 week and 4 week

  Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining)

Study Arms (4)

5s HIIT

EXPERIMENTAL

5s HIIT group will perform one bout of sprint running for 5-seconds followed by 25-second, resting of total 40 repetition.

Other: high-intensity interval training intervention

10s HIIT

EXPERIMENTAL

10s HIIT group will perform one bout of sprint running for 10-seconds followed by 50-second, resting of total 20 repetition.

Other: high-intensity interval training intervention

20s HIIT

EXPERIMENTAL

20s HIIT group will perform one bout of sprint running for 20-seconds followed by 100-second, resting of total 10 repetition.

Other: high-intensity interval training intervention

Control

EXPERIMENTAL

Control group

Other: high-intensity interval training intervention

Interventions

high-intensity interval training intervention OTHER

Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.

10s HIIT; 20s HIIT; 5s HIIT; Control

Eligibility Criteria

• Age: 18 Years - 25 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Young adults with obesity (Age 18 to 25 years old, BMI ≥ 30 kg/m2).

You may not qualify if:

• Syndromic obesity; 1) Any clinical symptoms including cognitive delay, 2) abnormalities in body structure(s), 3) organ-specific abnormalities (kidney, liver failure, excessive eating, and/or other signs of hypothalamic dysfunction such as fatigue, weakness and/or lack of interest in activities.
• Taking weight loss medication(s)
• Currently enrolled (or within previous 6 months) in a weight loss program;
• An underlying disease/medications (steroids, second generation psychotropic agents, hormonal contraception, statins, antihypertensive and antidiabetic medications) that could influence carbohydrate or lipid metabolism.
• Presence of cardiac pacemaker.
• Current or anticipated participation in another research that would interfere with any of the outcomes.
• Current or anticipated pregnancy.

Sponsors & Collaborators

• Syracuse University: lead

Study Sites (1)

Women's Building

Syracuse, New York, 13244, United States

RECRUITING

MeSH Terms

Conditions

Obesity; Cardiovascular Diseases; Metabolic Diseases

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Joon Young Kim, Ph.D

  Syracuse University, Departments of Exercise Science

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Myong Won Seo, Ph.D

CONTACT

3154012723; mseo04@syr.edu

Wonhee Cho, MS

CONTACT

6267270270; mseo04@syr.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 13, 2023
• First Posted: May 3, 2023
• Study Start: September 29, 2023
• Primary Completion: August 23, 2025
• Study Completion: December 10, 2025
• Last Updated: July 23, 2025

Record last verified: 2025-07

Locations

US (1)